Drugs / 323U66
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01138007 | Jun 2010 → Aug 2012 | major depressive disorder | GlaxoSmithKline | Completed | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 323U66 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01138007 ↗ |
| Route | Oral | “orally administered” NCT01138007 ↗ |